Free Trial

Cardlytics' (CDLX) "Sell (E+)" Rating Reiterated at Weiss Ratings

Cardlytics logo with Business Services background

Key Points

  • Cardlytics' stock has been reaffirmed with a "sell (E+)" rating by Weiss Ratings, indicating ongoing concerns about its performance.
  • Evercore ISI reduced the target price for Cardlytics from $3.00 to $2.00, with the consensus rating of the stock currently at "Hold" and an average price target of $2.25.
  • Recently, CEO Amit Gupta sold 68,685 shares of the company at an average price of $1.12, reducing his stake by 12.26% and highlighting potential insider selling pressure.
  • Five stocks we like better than Cardlytics.

Cardlytics (NASDAQ:CDLX - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by research analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Separately, Evercore ISI reduced their target price on shares of Cardlytics from $3.00 to $2.00 and set an "in-line" rating for the company in a report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $2.25.

Read Our Latest Analysis on Cardlytics

Cardlytics Trading Up 1.8%

NASDAQ:CDLX traded up $0.04 during trading hours on Wednesday, hitting $2.32. The company had a trading volume of 1,270,403 shares, compared to its average volume of 2,481,088. Cardlytics has a 52 week low of $0.85 and a 52 week high of $5.24. The company has a market capitalization of $123.52 million, a PE ratio of -0.64 and a beta of 1.45. The company has a debt-to-equity ratio of 2.87, a current ratio of 1.16 and a quick ratio of 1.16. The stock has a 50-day moving average price of $1.58 and a 200 day moving average price of $1.73.

Insider Transactions at Cardlytics

In other news, CEO Amit Gupta sold 68,685 shares of the firm's stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $1.12, for a total transaction of $76,927.20. Following the sale, the chief executive officer owned 491,759 shares of the company's stock, valued at approximately $550,770.08. This trade represents a 12.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders sold 159,335 shares of company stock valued at $204,204. 4.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Cardlytics

A number of institutional investors have recently made changes to their positions in CDLX. 683 Capital Management LLC grew its position in Cardlytics by 18.3% during the first quarter. 683 Capital Management LLC now owns 1,550,000 shares of the company's stock valued at $2,821,000 after acquiring an additional 240,000 shares during the period. LPL Financial LLC lifted its stake in shares of Cardlytics by 30.3% in the first quarter. LPL Financial LLC now owns 859,406 shares of the company's stock worth $1,564,000 after acquiring an additional 200,087 shares in the last quarter. Lane Generational LLC lifted its stake in shares of Cardlytics by 28.0% in the second quarter. Lane Generational LLC now owns 780,083 shares of the company's stock worth $1,283,000 after acquiring an additional 170,480 shares in the last quarter. Landscape Capital Management L.L.C. lifted its stake in shares of Cardlytics by 17.9% in the first quarter. Landscape Capital Management L.L.C. now owns 400,000 shares of the company's stock worth $728,000 after acquiring an additional 60,836 shares in the last quarter. Finally, Brooktree Capital Management raised its stake in Cardlytics by 8.3% during the second quarter. Brooktree Capital Management now owns 242,249 shares of the company's stock valued at $398,000 after buying an additional 18,624 shares in the last quarter. 68.10% of the stock is owned by institutional investors and hedge funds.

Cardlytics Company Profile

(Get Free Report)

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.

Recommended Stories

Analyst Recommendations for Cardlytics (NASDAQ:CDLX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cardlytics Right Now?

Before you consider Cardlytics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardlytics wasn't on the list.

While Cardlytics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Small-Cap Robotics Stocks with Massive Upside Ahead
The Rise of Aerial Robots: Drone Stocks Taking Off
3 Exceptional Growth Stocks to Hold for the Long Haul

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines